Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflammatory Drags (NSAID)) on the Symptom Relief of Lumbar DDD in China

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

478 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-06-30

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to observe the overall satisfaction of patients with degenerative disc disease after receiving triple therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

DDD (lumbar disc degenerative disease ) patients who have been prescribed triple therapy (MBL+ MYO+ NSAIDs) over 2 weeks of triple therapy were enrolled in the study. They were asked to assess their overall satisfaction degree on triple therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lumbar Disc Degenerative Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Lumbar disc degenerative disease Methycobal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lumbar disc degenerative disease

Triple therapy (MBL+ MYO+ NSAIDs) which prescribed by doctors (Drs) based on disease condition

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. lumbar degenerative disc disease (DDD)
2. patients who have been prescribed over 2 weeks of triple therapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Haibo Song

Role: STUDY_DIRECTOR

Eisai China Inc.

Review additional registry numbers or institutional identifiers associated with this trial.

EISAI-MBL-2010-1

Identifier Type: -

Identifier Source: org_study_id

Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflammatory Drags (NSAID)) on the Symptom Relief of Lumbar DDD in China

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

Lumbar disc degenerative disease

Eligibility Criteria

Inclusion Criteria

Sponsors

Eisai China Inc.

Responsible Party

Principal Investigators

Haibo Song

Locations

Dongfang Hospital

Huashan Hospital

Ruijin Hospital

Xinhua Hospital

Zhongshan Hospital

Shao Yifu Hospital of Zhejiang University

The 1st Hospital of Zhejiang University

The 1st People Hospital of Hanzhou

The 2nd Hospital of Zhejiang University

Traditional Chinese Medicine Hospital of Zhejiang

Countries

Other Identifiers

EISAI-MBL-2010-1